{"id":"W2512436288","doi":"10.1136/annrheumdis-2016-209709","title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"UCB Pharma; Genentech; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Santen; Pfizer; Abbott Japan; Novo Nordisk; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Placebo; Psoriatic arthritis; Adalimumab; Internal medicine; Psoriasis; Adverse effect; Immunology; Arthritis; Secukinumab; Pharmacology; Gastroenterology; Rheumatoid arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003293499,0.000491559,0.00199801,0.0000660384,0.0004292214,0.00003656664,0.0003914286,0.00008501449,0.0000545512],"category_scores_gemma":[0.0007953305,0.0001560296,0.0009929262,0.0001600949,0.0009257451,0.0001530631,0.00009114399,0.00008132252,0.000001028981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006218621,"about_ca_system_score_gemma":0.0001987487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003863412,"about_ca_topic_score_gemma":0.0001760683,"domain_scores_codex":[0.9968862,0.0004660581,0.001235324,0.0004748304,0.0005601135,0.0003774586],"domain_scores_gemma":[0.9922881,0.004508486,0.001665166,0.0009449383,0.0004642705,0.0001290883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8798062,0.00600375,0.0005189233,0.00002224222,0.006524158,0.000002699365,0.002920544,0.000005748291,0.00003969261,0.00006091572,0.0001278779,0.1039673],"study_design_scores_gemma":[0.9634958,0.01109609,0.01668139,0.001409365,0.002480635,0.000002798482,0.002585154,0.00006058568,0.001471432,0.0004365444,0.00009762543,0.0001825778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723312,0.004870378,0.00002187163,0.002403867,0.000429941,0.01578561,0.004095234,0.00001453773,0.00004738269],"genre_scores_gemma":[0.99274,0.005232751,0.00002921921,0.00006179745,0.0001312741,0.0015739,0.0001167939,0.00003110259,0.00008315807],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1037847,"threshold_uncertainty_score":0.6362701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05109430224959261,"score_gpt":0.3221726779938731,"score_spread":0.2710783757442805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}